rs12272917 (PPP6R3/LRP5): Bone Density and Lean Mass
Key takeaways
- This variant in the PPP6R3/LRP5 region is associated with both bone mineral density and lean muscle mass in children, placing it at the intersection of bone and muscle genetics
- A bivariate GWAS of 10,414 children found this locus has pleiotropic effects, meaning it influences bone density and lean mass at the same time
- The alternate allele increases PPP6R3 gene expression in ovary and whole blood, while having opposing directional effects on GAL expression across different tissues
- Evidence comes primarily from pediatric cohort studies; whether these effects persist identically into adulthood is not established by the reviewed studies
- No drug response or lifestyle intervention data have been reported for this specific variant
Key takeaways
- This variant in the PPP6R3/LRP5 region is associated with both bone mineral density and total-body lean mass in children, placing it at the intersection of bone and muscle genetics
- A bivariate GWAS of 10,414 children identified this locus as one of seven established BMD loci that also influence lean mass, demonstrating pleiotropic (multi-trait) effects
- GTEx data show the alternate allele increases PPP6R3 expression in ovary and whole blood, while GAL expression shifts direction depending on tissue type
- Evidence comes primarily from pediatric cohort studies; whether effects persist identically into adulthood is not established by the studies reviewed here
- No drug response or lifestyle intervention data have been reported for this specific variant
What the research says
rs12272917 sits within a genomic region encompassing PPP6R3 and LRP5 (hereafter "the locus"). A bivariate GWAS meta-analysis of total-body lean mass and total-body-less-head bone mineral density (TBLH-BMD) in 10,414 children identified this locus as one of seven established BMD loci with statistically significant pleiotropic effects on both traits PMID 28327566. The shared SNP heritability between TBLH-BMD and lean mass was estimated at 43% (95% CI: 29-56%), indicating that roughly half the genetic factors driving BMD in children also influence lean mass PMID 28327566. A separate longitudinal GWAS of heel BMD in 141,261 UK Biobank adults identified 52 candidate genes associated with BMD trajectory mean, situating this locus within a broader landscape of established BMD-associated genomic regions PMID 37624411.
Reported associations
- Total-body lean mass (pediatric): The locus showed pleiotropic association with total-body lean mass in a bivariate meta-analysis of 10,414 children, co-identified alongside its established effect on TBLH-BMD PMID 28327566
- Total-body-less-head bone mineral density (pediatric): The locus is one of seven established BMD loci showing joint effects on both bone density and lean mass in children (n=10,414) PMID 28327566
- Heel bone mineral density trajectory (adult): A longitudinal GWAS of 141,261 UK Biobank participants examined the genetic architecture of heel BMD mean and within-subject variability over time, identifying 52 candidate genes across multiple established BMD-associated regions PMID 37624411
- Skeletal site-specific BMD (pediatric): A meta-analysis in approximately 9,395 children found that established BMD loci can have substantially different effect sizes depending on whether upper limb, lower limb, or skull BMD is measured, providing context for interpreting association signals at established loci including this one PMID 26291518
Evidence quality
The strongest direct evidence for the PPP6R3/LRP5 locus comes from a 2017 bivariate GWAS meta-analysis of four pediatric cohorts totaling 10,414 children PMID 28327566. That study estimated SNP heritability of 43% (95% CI: 34-52%) for TBLH-BMD and 39% (95% CI: 30-48%) for total-body lean mass, with a shared genetic component of 43% (95% CI: 29-56%) PMID 28327566. A larger UK Biobank longitudinal analysis (n=141,261) identified 52 genes associated with BMD trajectory mean, with the three most significant signals reported at WNT16, FAM3C, and CPED1, rather than specifically foregrounding this region PMID 37624411. A pediatric meta-analysis of approximately 9,395 participants (combining ALSPAC and Generation R Study cohorts) found that some established BMD loci show substantially different effect sizes across skeletal sites, for example variants at CPED1 showed a stronger effect at skull and upper limb than at lower limb (P = 2.01 x 10^-37) PMID 26291518. All three studies recruited predominantly European-ancestry participants, and generalizability to other ancestries has not been established by the reviewed studies. No conflicting findings were identified across the three studies, though different age groups, skeletal measurement sites, and analytical methods limit direct numerical comparisons.
Tissue-specific expression effects
- PPP6R3: The alternate allele is associated with increased expression in ovary and whole blood tissues GTEx Portal
- GAL: The alternate allele is linked to reduced expression in tibial nerve and subcutaneous adipose tissue, and to increased expression in frontal cortex (BA9 region) and whole blood GTEx Portal
- ENSG00000260808 (an uncharacterized transcript): The alternate allele is associated with reduced expression in both tibial nerve and subcutaneous adipose tissues GTEx Portal
Lifestyle considerations
No lifestyle considerations on file for this variant.
Frequently asked questions
What is the PPP6R3 gene?
PPP6R3 encodes a regulatory subunit of protein phosphatase 6. Variants in the PPP6R3/LRP5 genomic region, including rs12272917, have been associated with bone mineral density and lean body mass in pediatric genome-wide association studies.
Is rs12272917 linked to osteoporosis?
Studies have found this variant region is associated with bone mineral density in children, and lower BMD is a recognized risk factor for osteoporosis in later life. The studies reviewed here do not directly link rs12272917 to fracture risk or an osteoporosis diagnosis.
Does rs12272917 affect muscle or lean body mass?
A bivariate GWAS meta-analysis of 10,414 children found that the PPP6R3/LRP5 locus has pleiotropic effects on both bone mineral density and total-body lean mass, meaning the same genomic region appears to influence bone and muscle simultaneously.
What does LRP5 do?
LRP5 (low-density lipoprotein receptor-related protein 5) is a co-receptor associated with bone formation pathways. rs12272917 lies in a genomic region encompassing both PPP6R3 and LRP5, and variants in this region have been consistently identified in genome-wide studies of bone mineral density.
What is a pleiotropic genetic variant?
A pleiotropic variant is one that statistically influences more than one biological trait. rs12272917 in the PPP6R3/LRP5 locus is considered pleiotropic because it has been associated with both bone mineral density and lean body mass in the same pediatric study populations.